Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Sibling Allogeneic Transplantation for Relapsed Hodgkin Lymphoma
NCT00907036Phase 2Unknown
- Sponsor
- Cancer Research UK
- Start
- Jul 2009
- Primary completion
- Jul 2015
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 2, open-label trial of fludarabine, melphalan and alemtuzumab in Hodgkin lymphoma (HL), sponsored by Cancer Research UK. Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Drugs
fludarabinemelphalanalemtuzumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00907036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00907036.